Solving NeuroPsychiatric Disorders through Targeted and Selective
NMDA Receptor Channel Inhibition
Our Mission
ReST develops breakthrough therapies to treat complex neurological and psychiatric disorders, by revisiting NMDA targeted selective inhibition. Our lead program RST-01 is focused on treatment of PTSD.
Executive Management
Gilles Rubinstenn
Co-Founder & Chief Executive Officer
Life Science Entrepreneur. Former Pharmaceutical BU director of M2I.
Inventor of FENM activity. Experienced manager of strategic alliances and R&D research consortia.
Florent Perin-Dureau
Co-Founder & Chief Medical Officer
Physician, anesthesiologist and intensivist. Former ANSM director for SNC products.
Expert in NMDAr structure and function. Specialist in regulatory affairs and clinical trial design.
Anthony Franco, J.D.
General Manager US
Seasoned Operations and Strategy Executive with over 20 years of experience across the Legal, Technical and Biotech industries.
Our Partners
